Avacta Therapeutics (AIM: AVCT) has reported encouraging clinical results from its ongoing Phase 1a/1b trial of faridoxorubicin (AVA6000), with median progression-free survival reaching 11.4 months in a selected group of
Avacta reports promising AVA6103 cancer trial progress with tumour responses in Enhertu-resistant models
Avacta Therapeutics (AIM: AVCT) has reported encouraging preclinical results for its experimental cancer treatment AVA6103, demonstrating tumour responses in models resistant to Enhertu, as the company advances its Phase 1
Avacta to present cancer trial survival data and AVA6103 study design at ESMO 2026
Avacta Therapeutics (AIM: AVCT) will present updated clinical data from its Faridoxorubicin (AVA6000) cancer programme and details of its AVA6103 trial at the European Society for Medical Oncology (ESMO) Congress
Share Talk Weekly Stock Market News Review, Sunday 11th October 2026
The FTSE 100 closed 1.06% higher at 10,552.05 on Friday, while the FTSE 250 gained 1.13% to 24,213.78. The rebound followed a volatile week dominated by oil prices, inflation concerns
Avacta Therapeutics Raises £12.5m as Trading Resumes After Capital Access Window
Avacta Therapeutics (AIM: AVCT) has conditionally raised £12.5 million gross through a placing and director subscription priced at 68p per share.
Avacta Therapeutics Seeks £12.5m to Extend Cash Runway Into Q2 2027
Avacta Therapeutics (AIM: AVCT) has launched an accelerated bookbuild and subscription seeking minimum gross proceeds of approximately £12.5 million.
RNS Hotlist with Zak Mir: AVCT, FORG, GRG, B90, CTAI, GRL & SEEN
(Alliance News) – The UK economy grew at a stronger pace than expected in the second quarter of the year, according to data from the Office for National Statistics on
Avacta Opens Capital Access Window Ahead of Equity Fundraise
Avacta (AIM: AVCT) currently expects its existing cash resources to last into early Q1 2027 and is continuing discussions with potential partners for its next-generation assets.
RNS Hotlist with Zak Mir: PRE, AVCT, AJAX, REV, THAT, HEX, UPL, ONDO & GWMO
Pensana (PRE) said that further to the recent RNS on the Cascade US$165 million investment with backing from the State of Qatar and the confirmation of USD$15 million received to
Avacta Group Further Demonstration of Potential of AVA6103
Avacta Therapeutics (AIM: AVCT) has presented the design of its Phase 1 FOCUS-01 trial and updated preclinical data supporting AVA6103 in pancreatic ductal adenocarcinoma at the AACR Conference on Pancreatic
RNS Hotlist with Zak Mir: PXEN, HEX, COBR, EPP, AVCT, FTC, RIFT, HUI, ROCK & GWMO
Alliance News: UK consumer price inflation accelerates to 3.1% year-on-year in August from 2.9% in July, in line with market expectations cited by FXStreet, according to the Office for National Statistics.
Avacta Reports Clinical Proof of Mechanism for AVA6103 in Phase 1 Trial
Avacta Therapeutics (AIM: AVCT) has reported clinical proof of mechanism for AVA6103, its next-generation pre|CISION® peptide-drug conjugate, from the ongoing Phase 1 FOCUS-01 trial.